Arkolith/Insider Trading/EIGR/Form 4

Dietz Thomas John

DirectorEiger BioPharmaceuticals, Inc. (EIGR) · full profile →Form 4 · filed Apr 12, 2021
Net Buying
Open-Market Buys
$21K
Open-Market Sells
$0
Net Open-Market Flow
$21K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 9, 2021Buy(P)2K$8.48$13K37K
Apr 9, 2021Buy(P)1K$8.50$9K38K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-21-026382) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML